Enertopia (ENRT) 10-Q 14 Apr 15 2015 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Feb. 28, 2015	Mar. 15, 2015
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	28-Feb-15
Trading Symbol	enrt
Entity Registrant Name	Enertopia Corp.
Entity Central Index Key	1346022
Current Fiscal Year End Date	-23
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		77,908,460
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well Known Seasoned Issuer	No
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q2

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Feb. 28, 2015	Aug. 31, 2014
Current
Cash and cash equivalents	$370,768	$888,122
Owned securities	293,750	323,750
Accounts receivable	57,934	42,264
Prepaid expenses and deposit	67,017	234,091
Inventory	17,864	0
Total current assets	807,333	1,488,227
Non-Current
Long term investments - GSWPS	1	1
Medical Marijuana Assets	390,272	774,271
Total Assets	1,197,606	2,262,499
Current
Accounts payable	234,016	226,916
Deferred Revenues	260,000	280,000
Due to related parties	72,910	72,910
Total Current Liabilities	566,926	579,826
Total Liabilities	566,926	579,826
STOCKHOLDERS' EQUITY
Share capital Authorized: 200,000,000 common shares with a par value of $0.001 per share Issued and outstanding: 77,318,460 common shares at February 28, 2015 and August 31,2014: 90,870,747	77,318	90,870
Additional paid-in capital	12,620,679	14,070,611
Shares to be returned	0	-1,713,145
Deficit accumulated during the exploration stage	-12,067,317	-10,765,663
Total Stockholders' Equity	630,680	1,682,673
Total Liabilities and Stockholders' Equity	$1,197,606	$2,262,499

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Feb. 28, 2015	Aug. 31, 2014
Common Stock, Shares Authorized	200,000,000	200,000,000
Common Stock, Par Value Per Share	$0.00	$0.00
Common Stock, Shares, Issued	77,318,460	90,870,747
Common Stock, Shares, Outstanding	77,318,460	90,870,747

CONSOLIDATED_STATEMENTS_OF_STO

CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY (USD $)	COMMON STOCK [Member]	ADDITIONAL PAID-IN CAPITAL [Member]	STOCK TO BE ISSUED [Member]	DEFICIT ACCUMULATED DURING EXPLORATION STAGE [Member]	Total
Beginning Balance at Nov. 24, 2004
Issuance of common stock for cash at $0.02 per share on March 22, 2005	$5,468	$103,882			$109,350
Issuance of common stock for cash at $0.02 per share on March 22, 2005 (Shares)	5,467,500
Issuance of common stock for cash at $0.30 per share on April 6, 2005	1,112	332,638			333,750
Issuance of common stock for cash at $0.30 per share on April 6, 2005 (Shares)	1,112,500
Stock to be issued		37,375	125		37,500
Stock to be issued (Shares)	125,000
(Loss) for the period				-167,683	-167,683
Ending Balance at Aug. 31, 2005	6,580	473,895	125	-167,683	312,917
Ending Balance (Shares) at Aug. 31, 2005	6,705,000
Stock issued on September 29, 2005	125		-125
(Loss) for the period				-200,091	-200,091
Ending Balance at Aug. 31, 2006	6,705	473,895		-367,774	112,826
Ending Balance (Shares) at Aug. 31, 2006	6,705,000
Units issued for cash at $0.50 per unit to related parties on March 6, 2007 (included stock based compensation of $116,959)	93	163,236			163,329
Units issued for cash at $0.50 per unit to related parties on March 6, 2007 (included stock based compensation of $116,959) (Shares)	92,740
Stock issued for property on April 18, 2007	250	274,750			275,000
Stock issued for property on April 18, 2007 (Shares)	250,000
Units issued for cash at $0.50 per unit on April 19, 2007	100	49,900			50,000
Units issued for cash at $0.50 per unit on April 19, 2007 (Shares)	100,000
Units issued for cash at $0.50 per unit on August 31, 2007	600	299,400			300,000
Units issued for cash at $0.50 per unit on August 31, 2007 (Shares)	600,000
Imputed interest from non-interest bearing loan		3,405			3,405
(Loss) for the period				-607,397	-607,397
Ending Balance at Aug. 31, 2007	7,748	1,264,586		-975,171	297,163
Ending Balance (Shares) at Aug. 31, 2007	7,747,740
Units issued for acquisition at $0.42 per unit on November 30, 2007	6,905	2,893,195			2,900,100
Units issued for acquisition at $0.42 per unit on November 30, 2007 (Shares)	6,905,000
Imputed interest from non-interest bearing loan		7,139			7,139
Stock-based compensation on 1,785,000 options granted		104,257			104,257
(Loss) for the period				-372,535	-372,535
Ending Balance at Aug. 31, 2008	14,653	4,269,177		-1,347,706	2,936,124
Ending Balance (Shares) at Aug. 31, 2008	14,652,740
Imputed interest from non-interest bearing loan		4,410			4,410
Stock Based Compensation		35,780			35,780
(Loss) for the period				84,233	84,233
Ending Balance at Aug. 31, 2009	14,653	4,309,367		-1,263,473	3,060,547
Beginning Balance (Shares) at Aug. 31, 2009	14,652,740
Imputed interest from non-interest bearing loan		2,442			2,442
Gain on settlement of the amount due to related parties		34,542			34,542
Stock issued for acquisition at $0.20 per share on February 28, 2010	500	124,500			125,000
Stock issued for acquisition at $0.20 per share on February 28, 2010 (Shares)	500,000
Units issued for cash at $0.15 per unit on May 31, 2010	557	83,068			83,625
Units issued for cash at $0.15 per unit on May 31, 2010 (Shares)	557,500
Stock Based Compensation		78,858			78,858
(Loss) for the period				-2,955,141	-2,955,141
Ending Balance at Aug. 31, 2010	15,710	4,632,777		-4,218,614	429,873
Ending Balance (Shares) at Aug. 31, 2010	15,710,240
Debt settlement on November 22, 2010	63	9,313			9,376
Debt settlement on November 22, 2010 (Shares)	62,500
Debt settlement on November 19, 2010	100	14,900			15,000
Debt settlement on November 19, 2010 (Shares)	100,000
Share Subscriptions on March 3, 2011	8,729	885,264			893,993
Share Subscriptions on March 3, 2011 (Shares)	8,729,000
Share issuance costs		-96,490			-96,490
Warrants issued on March 3, 2011		-848,459			-848,459
Common Shares cancelled on January 1, 2011	-1,000	1,000
Common Shares cancelled on January 1, 2011 (Shares)	-1,000,000
Debt settlement on March 16, 2011	78	12,422			12,500
Debt settlement on March 16, 2011 (Shares)	78,125
Debt settlement on April 27, 2011	360	157,412			157,772
Debt settlement on April 27, 2011 (Shares)	360,000
Debt settlement on April 27 2011	100	45,900			46,000
Debt settlement on April 27 2011 (Shares)	100,000
Shares issued Wildhorse on April 11, 2011	500	74,500			75,000
Shares issued Wildhorse on April 11, 2011 (Shares)	500,000
Share issuance correction on Jun 4, 2011	4	-4
Share issuance correction on Jun 4, 2011 (Shares)	4,000
Stock Based Compensation		254,443			254,443
(Loss) for the period				-165,405	-165,405
Ending Balance at Aug. 31, 2011	24,644	5,142,978		-4,384,019	783,603
Ending Balance (Shares) at Aug. 31, 2011	24,643,865
Shares issued Altar on October 11, 2011	100	9,900			10,000
Shares issued Altar on October 11, 2011 (Shares)	100,000
Shares issued Wildhorse on March 30, 2012	150	14,850			15,000
Shares issued Wildhorse on March 30, 2012 (Shares)	150,000
Shares issued Tom Ihrke on April 10, 2012	94	9,281			9,375
Shares issued Tom Ihrke on April 10, 2012 (Shares)	93,750
Shares subscription for cash on April 13, 2012	2,080	191,499			193,579
Shares subscription for cash on April 13, 2012 (Shares)	2,080,000
Shares subscription for cash on July 27, 2012	600	29,400			30,000
Shares subscription for cash on July 27, 2012 (Shares)	600,000
Shares subscription for cash on August 24, 2012	160	7,840			8,000
Shares subscription for cash on August 24, 2012 (Shares)	160,000
Stock Based Compensation		66,953			66,953
(Loss) for the period				-1,009,735	-1,009,735
Ending Balance at Aug. 31, 2012	27,828	5,472,701		-5,393,754	106,775
Ending Balance (Shares) at Aug. 31, 2012	27,827,615
Shares issued for cash September 28, 2012	1,074	48,676			49,750
Shares issued for cash September 28, 2012 (Shares)	1,074,500
Shares issued Altar on November 24, 2012	100	5,900			6,000
Shares issued Altar on November 24, 2012 (Shares)	100,000
Shares issued for cash November 15, 2012	1,152	49,498			50,650
Shares issued for cash November 15, 2012 (Shares)	1,152,300
Shares issued to Mark Snyder	160	15,840			16,000
Shares issued to Mark Snyder (Shares)	160,000
Debt settlement on March 1, 2013		30,280			30,280
(Loss) for the period				-730,904	-730,904
Ending Balance at Aug. 31, 2013	30,314	5,622,895		-6,124,658	-471,449
Ending Balance (Shares) at Aug. 31, 2013	30,314,415
Shares issued to Downhole Energy	100	1,900			2,000
Shares issued to Downhole Energy (Shares)	100,000
Shares issued to Stewart Briggs/Olibri	750	36,750			37,500
Shares issued to Stewart Briggs/Olibri (Shares)	750,000
Shares issued for MM Assets	10,000	190,000			200,000
Shares issued for MM Assets (Shares)	10,000,000
Shares issued for Investor Relations	200	13,800			14,000
Shares issued for Investor Relations (Shares)	200,000
Shares issued for cash for PP on Nov 18	2,720	133,280			136,000
Shares issued for cash for PP on Nov 18 (Shares)	2,720,000
Shares issued for cash for PP on Dec 23	2,528	113,732			116,260
Shares issued for cash for PP on Dec 23 (Shares)	2,528,000
Shares issued per Agreement with DS	250	37,250			37,500
Shares issued per Agreement with DS (Shares)	250,000
Shares issued per JV with WOM	5,000	895,000			900,000
Shares issued per JV with WOM (Shares)	5,000,000
Shares issued for cash for PP on Jan 31	4,292	395,292			399,584
Shares issued for cash for PP on Jan 31 (Shares)	4,292,000
Shares issued for warrant conversion	1,127	214,973			216,100
Shares issued for warrant conversion (Shares)	1,126,500
Shares issued for option conversion	450	43,800			44,250
Shares issued for option conversion (Shares)	450,000
Shares issued for cash for PP on Feb 13	12,946	1,182,070			1,195,016
Shares issued for cash for PP on Feb 13 (Shares)	12,946,000
Shares issued as per Agreement with Agora	54	12,446			12,500
Shares issued as per Agreement with Agora (Shares)	54,347
Shares issued per JV Agreement with GCL	10,000	2,090,000			2,100,000
Shares issued per JV Agreement with GCL (Shares)	10,000,000
Shares issued per JV Agreement with WOM	1,000	599,000			600,000
Shares issued per JV Agreement with WOM (Shares)	1,000,000
Shares issued for warrant conversion (Two)	5,828	909,143			914,971
Shares issued for warrant conversion (Two) (Shares)	5,827,855
Shares issued for option conversion (Two)	425	83,800			84,225
Shares issued for option conversion (Two) (Shares)	425,000
Shares issued for warrant conversion (Three)	252	24,948			25,200
Shares issued for warrant conversion (Three) (Shares)	252,000
Shares issued as per agreement with R. Chadwick	100	59,900			60,000
Shares issued as per agreement with R. Chadwick (Shares)	100,000
Shares issued as per agreement with Dr. Melamede	250	169,750			170,000
Shares issued as per agreement with Dr. Melamede (Shares)	250,000
Shares issued as per various Ontario agreements	623	212,676			213,299
Shares issued as per various Ontario agreements (Shares)	623,297
Shares issued as per Agreement with Agora (Two)	73	13,053			13,126
Shares issued as per Agreement with Agora (Two) (Shares)	72,917
Shares issued as per Agreement with Emerging LLC	750	119,250			120,000
Shares issued as per Agreement with Emerging LLC (Shares)	750,000
Shares issued as per various Ontario agreements (Two)	720	100,080			100,800
Shares issued as per various Ontario agreements (Two) (Shares)	720,000
Shares issued per LOI Burlington	118	22,382			22,500
Shares issued per LOI Burlington (Shares)	118,416
WOM JV Termination, shares back to Treasury	-15,127,287	-1,667,418			-1,682,545
WOM JV Termination, shares back to Treasury (Shares)	-15,127
Shares returned for contract cancellation C. Hornung	-90,000	-30,510			-30,600
Shares returned for contract cancellation C. Hornung (Shares)	-90
Stock Based Compensation		773,441			773,441
(Loss) for the period				-4,641,005	-4,641,005
Ending Balance at Aug. 31, 2014	75,653	14,070,611		-10,765,663	1,682,673
Ending Balance (Shares) at Aug. 31, 2014	75,653,460
Stock Based Compensation		177,596			177,596
Shares issued for PP on January 30	1,665	70,400			72,065
Shares issued for PP on January 30 (Shares)	1,665,000
(Loss) for the period				-1,301,654	-1,301,654
Ending Balance at Feb. 28, 2015	$77,318	$12,620,679		($12,067,317)	$630,680
Ending Balance (Shares) at Feb. 28, 2015	77,318,460

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		6 Months Ended		123 Months Ended
	Feb. 28, 2015	Feb. 28, 2014	Feb. 28, 2015	Feb. 28, 2014	Feb. 28, 2015
Revenue
Non-renewal energy - natural gas and oil revenue	$0	$0	$0	$0	$374,342
Renewable energy - service revenue	0	0	0	0	32,119
Total Revenue	0	0	0	0	406,461
Non-renewable energy:
Natural gas and oil operating costs and royalties	0	0	0	0	141,197
Depletion	0	0	0	0	298,489
Write-down in carrying value of oil and gas property	0	0	0	0	293,436
Renewable energy	0	0	0	0	48,050
Cost of Revenue	0	0	0	0	781,172
Gross Profit	0	0	0	0	-374,711
Expenses
Accounting and audit	5,212	3,951	40,628	22,675	471,859
Sales & Marketing	183	0	183	0	3,228
Advertising & Promotions	83,060	44,197	131,810	73,458	383,080
Bank charges and interest expense	771	2,878	1,164	3,224	72,143
Consulting	193,358	124,784	591,555	190,805	4,155,280
Mineral exploration costs	0	0	0	0	520,869
Fees and dues	15,902	6,722	24,654	15,668	227,463
Insurance	1,826	4,586	3,875	8,786	98,236
Investor relations	11,738	12,629	18,473	26,629	186,471
Legal and professional	5,444	9,772	28,965	9,772	331,130
Office and miscellaneous	1,487	10,149	7,704	12,201	98,667
Research and development costs for V_Love	5,364	0	5,364	0	5,364
Rent	21,257	1,958	45,352	2,504	186,421
Telephone	1,056	229	1,845	229	23,968
Training & Conferences	394	4,525	394	9,378	48,782
Travel	3,059	10,848	5,688	11,308	180,683
Total expenses	350,111	237,228	907,654	386,637	6,993,644
(Loss) for the period before other items	-350,111	-237,228	-907,654	-386,637	-7,368,355
Other income (expense)
Other income	10,000	0	20,000	0	101,354
Impairment of long term investments	0	0	0	0	-722,889
MMJ license expenses	0	-76,594	-384,000	-76,594	-2,266,860
Others	0	0	0	0	22,775
Equity interest pick up	0	-8,982	0	-8,982	-17,744
Gain on owned securities	0	0	-30,000	0	-313,082
Gain on disposition of oil and gas interests	0	0	0	0	522,976
Revaluation of warrants liability	0	0	0	0	896,019
Write down of oil and gas properties	0	0	0	0	-2,921,511
Net loss and comrehensive loss for the period	($340,111)	($322,804)	($1,301,654)	($472,213)	($12,067,317)
Basic and diluted income (loss) per share	($0.01)	($0.01)	($0.02)	($0.01)
Weighted average number of common shares outstanding - basic and diluted	75,921,710	52,105,091	79,546,951	42,885,978

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	6 Months Ended		123 Months Ended
	Feb. 28, 2015	Feb. 28, 2014	Feb. 28, 2015
Cash flows used in operating activities
Net Income (loss)	($1,301,654)	($472,213)	($12,067,317)
Changes to reconcile net loss to net cash used in operating activities
Consulting - Stock based compensation	177,596	133,214	1,608,287
Depletion	0	0	298,489
Write down in carrying value of oil and gas properties	0	0	293,436
Stock issued for services	0	0	37,500
MMJ expenses	384,000	0	1,716,010
Write down of oil and gas properties	0	0	2,921,511
Gain on disposition of oil and gas properties	0	0	-522,976
Fair value of warrants liabilities	0	0	-896,019
Gain on owned securities	30,000	0	313,082
Equity pick-up	0	8,982	17,744
Impairment of long term investments	0	0	271,295
Imputed interest	0	0	17,396
Accrued loan interest	0	0	17,928
Other non-cash activities	0	0	540,166
Change in non-cash working capital items:
Accounts receivable	-15,670	-5,900	-27,994
Prepaid expenses and deposit	128,884	83	139,680
Deferred revenues	-20,000	0	-20,000
Accounts payable and accrued liabilities	7,098	-69,077	223,851
Due to related parties	0	12,062	95,496
Net cash (used in) operating activities	-609,746	-392,849	-5,022,435
Cash flows from (used in) investing activities
Proceeds from sale of marketable securities	0	0	56,241
Oil and gas properties acquisition and divestment	0	0	-345,180
Proceeds from sale of oil and gas interests	0	0	521,545
Mineral resource properties acquisition	0	0	-231,843
Investment in GSWPS	0	0	-103,500
Investment in Pro Eco	0	10,004	-34,995
Investment in Medical Marijuana Operations	0	-716,610	-6,270
Cash provided in connection with business acquisition	0	0	201,028
Net cash from (used in) investing activities	0	-706,606	57,026
Cash flows from financing activities
Promissory notes - related party	0	-47,380	2,665
Net Proceeds from Options exercised	0	44,250	128,500
Net Proceeds from Warrants exercised	0	216,100	1,156,246
Net proceeds from subscriptions received	92,392	1,855,460	4,048,766
Net cash from financing activities	92,392	2,068,430	5,336,177
Increase (Decrease) in cash and cash equivalents	-517,354	968,975	370,768
Cash and cash equivalents, beginning of period	888,122	1,341	0
Cash and cash equivalents, end of period	370,768	970,316	370,768
Supplemental information of cash flows
Interest paid in cash	0	0	0
Income taxes paid in cash	$0	$0	$0

ORGANIZATION

ORGANIZATION	6 Months Ended
	Feb. 28, 2015
ORGANIZATION [Text Block]	1	ORGANIZATION
	The unaudited interim consolidated financial statements for the period ended February 28, 2015 included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with United States generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. These unaudited interim consolidated financial statements should be read in conjunction with the August 31, 2014 audited annual consolidated financial statements and notes thereto.
	The Company was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. The Company was an independent natural gas and oil company engaged in the exploration, development and acquisition of natural gas and oil properties in the United States and Canada. In the fiscal year 2010, the Company shifted its strategic plan from its non-renewal energy operations to its planned renewal energy operations and natural resource acquisition and development. In late summer of 2013, the Company added another business sector in its entrance to medical marijuana and alternative health and wellness and is considered a development stage company. The Company has offices in Vancouver and Kelowna, B.C., Canada.
	Effective September 25, 2009, we effected one (1) for two (2) share consolidation of our authorized and issued and outstanding common stock.
	On February 8, 2010, the Company changed its name from Golden Aria Corp. to Enertopia Corp.
	On February 22, 2010, the Company increased its authorized share capital to 200,000,000 common shares.

GOING_CONCERN_UNCERTAINTY

GOING CONCERN UNCERTAINTY	6 Months Ended
	Feb. 28, 2015
GOING CONCERN UNCERTAINTY [Text Block]	2	GOING CONCERN UNCERTAINTY
	The accompanying unaudited interim consolidated financial statements have been prepared on a going concern basis which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business for the foreseeable future. The Company incurred a net loss of $1,301,654 for the six months ended February 28, 2015 [net loss of $472,213 for the six months ended February 28, 2014] and as at February 28, 2015 has incurred cumulative losses of $12,067,317 that raises substantial doubt about its ability to continue as a going concern. Management has been able, thus far, to finance the operations through equity financing and cash on hand. There is no assurance that the Company will be able to continue to finance the Company on this basis.
	In view of these conditions, the ability of the Company to continue as a going concern is in substantial doubt and dependent upon its ability to generate sufficient cash flow to meet its obligations on a timely basis, to obtain additional financing as may be required, to receive the continued support of the Company’s shareholders, and ultimately to obtain successful operations. There are no assurances that we will be able to obtain further funds required for our continued operations. As noted herein, we are pursuing various financing alternatives to meet our immediate and long-term financial requirements. There can be no assurance that additional financing will be available to us when needed or, if available, that it can be obtained on commercially reasonable terms. If we are not able to obtain the additional financing on a timely basis, we will be unable to conduct our operations as planned, and we will not be able to meet our other obligations as they become due. In such event, we will be forced to scale down or perhaps even cease our operations. There is significant uncertainty as to whether we can obtain additional financing. These unaudited interim consolidated financial statements do not give effect to any adjustments which would be necessary should the Company be unable to continue as a going concern and therefore be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts different from those reflected in the accompanying unaudited interim consolidated financial statements.

SIGNIFICANT_ACCOUNTING_POLICIE

SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Feb. 28, 2015
SIGNIFICANT ACCOUNTING POLICIES [Text Block]	3	SIGNIFICANT ACCOUNTING POLICIES
	a)	Basis of Consolidation
	The unaudited interim consolidated financial statements include the financial statements of the Company and its wholly-owned subsidiaries, Thor Pharma Corp. and Target Energy, Inc. Target Energy, Inc. was dissolved effective November 4, 2013 with no significant accounting impact. The unaudited interim consolidated financial statements also include the equity interests of Global Solar Water Power Systems Inc. Global Solar Water Power Systems Inc. has been written down to $1. All significant inter-company balances and transactions have been eliminated.
	b)	New Accounting Pronouncements
	FASB ASU 2014-09, “Revenue from Contracts with Customers,” was issued May 2014 and updates the principles for recognizing revenue. The ASU will supersede most of the existing revenue recognition requirements in U.S. GAAP and will require entities to recognize revenue at an amount that reflects the consideration to which the Company expects to be entitled in exchange for transferring goods or services to a customer. This ASU also amends the required disclosures of the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The guidance is effective for annual periods beginning after December 15, 2016, including interim periods within that period. Early adoption is not permitted under U.S. GAAP. The Company is determining its implementation approach and evaluating the potential impacts of the new standard on its existing revenue recognition policies and procedures.
	FASB ASU 2014-12, “Compensation - Stock Compensation (Topic 718), Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period,” was issued June 2014. This guidance was issued to resolve diversity in accounting for performance targets. A performance target in a share-based payment that affects vesting and that could be achieved after the requisite service period should be accounted for as a performance condition and should not be reflected in the award’s grant date fair value. Compensation cost should be recognized over the required service period, if it is probable that the performance condition will be achieved. The guidance is effective for annual periods beginning after December 15, 2015 and interim periods within those annual periods. The Company does not anticipate a significant impact upon adoption.
	FASB ASU 2014-15, “Presentation of Financial Statements-Going Concern (Subtopic 205-40) Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” which was issued September 2014. This provides guidance on determining when and how to disclose going-concern uncertainties in the financial statements. The new standard requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date the financial statements are issued. An entity must provide certain disclosures if conditions or events raise substantial doubt about the entity’s ability to continue as a going concern. The ASU applies to all entities and is effective for annual periods ending after December 15, 2016, and interim periods thereafter, with early adoption permitted. The Company does not anticipate a significant impact upon adoption.
	Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s financial statements upon adoption.

OWNED_SECURITIES

OWNED SECURITIES	6 Months Ended
	Feb. 28, 2015
OWNED SECURITIES [Text Block]	4	OWNED SECURITIES
	As at February 28, 2015 owned securities consist of 375,000 common shares of Cheetah Oil & Gas Ltd. obtained through the disposal of the Company’s oil and gas properties in Mississippi in 2010. The Company classified the securities owned as held-for-trade and recorded at fair value.
	The fair value of the common shares of Cheetah Oil & Gas Ltd. was $0.01 per share as at February 28, 2015 ( August 31, 2014 - $0.01) .
	As at February 28, 2015 owned securities consist of 1,000,000 common shares of Lexaria Corp. obtained through Definitive Agreements as per Note 6 (c). The Company classified the securities owned as held-for-trade and recorded at fair value.
	The fair value of the common shares of Lexaria Corp. was $0.09 per share as ar February 28, 2015.
	As at February 28, 2015 owned securities consist of 500,000 restricted common shares of Lexaria Corp. at deemed price of $0.40 per share. Such shares to be released to the Company when a valid license from Health Canada, which designate Enertopia as a Licensed Producer pursuant to Canada's Marijuana for Medical Purposes Regulations (the “MMPR license”), has been received. In the event of MMPR license has not been received within 24 months of the date of this agreement, such shares will be cancelled and returned to treasury. Restricted shares are not within the scope of ASC 320-10 and are therefore accounted for at cost less other than temporally impairment if the restriction does not terminated within one year. No other than temporally impairment incurred as at February 28, 2015. Also see Note 6 (d).

LONG_TERM_INVESTMENTS

LONG TERM INVESTMENTS	6 Months Ended
	Feb. 28, 2015
LONG TERM INVESTMENTS [Text Block]	5	LONG TERM INVESTMENTS
	Global Solar Water Power Systems Inc. (“GSWPS”)
	On February 28, 2010, the Company entered into an Asset and Share Purchase Agreement with the Company’s former chief technical officer - Mr. Mark Snyder to acquire up to 20% ownership interest of GSWPS.
	During the year ended August 31, 2013, based on the management’s assessment of GSWPS’s current operations, the Company decided to write down long-term investment in GSWPS to $1.

MEDICAL_MARIJUANA_INVESTMENT

MEDICAL MARIJUANA INVESTMENT	6 Months Ended
	Feb. 28, 2015
MEDICAL MARIJUANA INVESTMENT [Text Block]	6	MEDICAL MARIJUANA INVESTMENT
	(a)	The Company has entered into a Joint Venture Agreement (the “ WOM Agreement”) on January 16, 2014 with World of Marijuana Productions Ltd. (“WOM”) where the Company can acquire up to 51% of the Joint Venture business ownership interest. WOM is expected to acquire a licence issued by Health Canada (the "Licence") to allow for WOM to operate a business of legally producing, manufacturing, propagating, importing/exporting, testing, researching and developing, and selling marijuana (the “WOM Business”) which shall be located at 33420 Cardinal Street, Mission, British Columbia (the "Premises"). Both parties entered into a non-binding Letter Of Intent dated for reference the 1 st day of November, 2013 (the "LOI") which shall be superseded by the WOM Agreement. Both parties entered into the WOM Agreement which set out the terms and conditions in which the Company may acquire up to a 51% ownership interest in the Joint Venture WOM Business. The Effective Date" means the first business day following the day on which WOM has received the final and duly issued Licence from Health Canada and has notified Enertopia of such receipt. The execution date (the “Execution Date”) is upon signing of this WOM Agreement.
	The following are the terms of the WOM Agreement:
	Enertopia shall purchase its Interest in the Business as set out below, provided that all cash payments are payable directly to WOM by way of wire transfer:
		i)	10,000,000 shares of the restricted common stock of Enertopia (the "Shares") to 0984329 B.C. Ltd ("098") at the direction of WOM at the time of execution of the LOI (the "LOI Shares") (Completed);
		ii)	Issuance of 5,000,000 Shares to 098 and payment of $100,000 to WOM upon signing of this WOM Agreement the Execution Date which Shares will be held in escrow (the "Escrow Shares") by Enertopia's solicitors until such time as the Effective Date has occurred. Upon occurrence of the Effective Date, the Escrow Shares will be released from escrow; (Completed)
		iii)	Payment to WOM of $75,000 by January 31, 2014 in exchange for which Enertopia will be granted a 30% Interest in the WOM Business;(Completed)
		iv)	Issue 1,000,000 Shares to 098 and pay $200,000 to WOM on or before the date that is six months from the Execution Date in exchange for which Enertopia shall be granted a further 1% Interest in the WOM Business; (Completed)
		v)	Issue 1,000,000 Shares to 098 and pay $200,000 to WOM on or before the one year anniversary of the Execution Date in exchange for which Enertopia shall be granted a further 2% Interest in the WOM Business;
		vi)	Issue 1,000,000 Shares to 098 and $200,000 to WOM on or before the second year anniversary of the Execution Date in exchange for which Enertopia shall be granted a further 6% Interest in the WOM Business;
		vii)	Issue 1,000,000 Shares to 098 and $300,000 to WOM on or before the third year anniversary of the Execution Date in exchange for which Enertopia shall be granted a further 6% Interest in the WOM Business;
		viii)	Issue 1,000,000 Shares to 098 and $300,000 to WOM on or before the fourth year anniversary of the Execution Date in exchange for which Enertopia shall be granted a further 6% interest in the WOM Business for a total of 51% Interest to be held by Enertopia at such time;
		ix)	Following the Effective Date and subject to any required stock exchange approvals, Enertopia shall appoint Mathew Chadwick, the current sole director of WOM (the "Appointee"), to the board of directors of Enertopia. The Appointee will hold office until the next annual meeting of the shareholders of Enertopia unless his office is earlier vacated in accordance with applicable corporate law. Enertopia shall include the Appointee as one of the management nominees put forth by Enertopia at each shareholder meeting at which the election of directors is an item of business, provided however, that the Appointee shall only be entitled to serve as a director of Enertopia as long as this Agreement is in good standing, full force and effect;
		x)	WOM shall not, at any time following the Effective Date and during the course this Agreement remains in effect, issue, split, reverse split, hypothecate or otherwise transact any of its share capital, under any circumstance, without the prior written consent of Enertopia; and
		xi)	WOM shall use the first $375,000 paid by Enertopia pursuant to the term of the WOM Agreement hereof to upgrade the Business as may be required pursuant to Health Canada stipulations or as my otherwise required to advance the Business.
	The license application for the WOM joint venture was submitted in October 2013. To date the WOM joint venture has been financed by our Company in the amount of $375,000. The $375,000 budget is intended to fund the joint venture through completion of facility upgrades and completion of the licensing process. On September 18, 2014 we announced that we have provided notice to WOM alleging default under the terms of the joint venture agreement for, among other things, their failure to provide financial information in regards to the funding, expenses and operation of the joint venture. WOM has provided notice in response disputing their default, and we are currently in correspondence with WOMs attorney.
	On October 16, 2014, the Company entered into a termination and settlement agreement, dated effective October 14, 2014, with WOM and Mathew Chadwick (the “ Settlement Agreement ”), pursuant to which the parties have entered into mutual releases, Mr. Chadwick has resigned from our board of directors and as an officer of the Company, and WOM has returned back to the treasury of the Company 15,127,287 common shares that had been issued to it. Given the foregoing, all relationships between the parties, including but not limited to the WOM Agreement in regards to the Joint Venture business, have been terminated. On August 31, 2014, the Company had recognized impairment loss for total amount of $392,454.
	(b)	On February 28, 2014, the Company has entered into a Joint Venture Agreement ("the GCL Agreement") with The Green Canvas Ltd. ("GCL") (collectively, the "Parties") with regard to the acquisition (the "Acquisition") by Enertopia of up a 75% interest in the business of GCL (the "GCL Business"), being the business of legally producing, manufacturing, propagating, importing/exporting, testing, researching and developing, and selling marijuana for medical purposes.
	The Company shall be entitled to acquire up to 75% ownership interest in the GCL Business (an "Ownership Interest") as follows:
		a)	Payment of $100,000 at the time of execution of the LOI (paid);
		b)	Either concurrently with or immediately following the Execution Date, Enertopia shall complete the following in return for which Enertopia will be granted and vested with a 49% Ownership Interest in the Business:
		(i)	issue to GCL an aggregate of 10,000,000 common shares of Enertopia ("Shares"); and (issued)
		(ii)	pay to GCL the aggregate sum of $500,000, the full amount of which, less the sum of $113,400 payable to Wolverton Securities as a finder's fee, shall be used by GCL to upgrade the GCL Business as may be necessary pursuant to MMPR requirements or as may otherwise be required to advance the GCL Business.(paid)
		c)	An aggregate of 6,400,000 of the Shares issued pursuant to the term of CGL Agreement shall be held in escrow (the "Escrow Shares") by the Company’s solicitors until the Effective Date. Upon occurrence of the Effective Date, Enertopia will cause its solicitors to release the Escrow Shares from escrow. (paid)
		d)	On or before the first anniversary of the Execution Date, Enertopia shall pay the sum of $250,000 to GCL and issue 3,000,000 Shares to GCL, in return for which Enertopia will be granted and vested with an additional 2% Ownership Interest for a total Ownership Interest of 51% at such time.
		e)	On or before the second anniversary of the Execution Date, pay the sum of $150,000 to GCL and issue 3,000,000 Shares to GCL, in return for which Enertopia will be granted and vested with an additional 9% Ownership Interest for a total Ownership Interest of 60% at such time.
		f)	Upon earning a 60% Ownership Interest on or before the second anniversary of the Execution Date in accordance with Sections (d) and (e), Enertopia shall have the option to acquire an additional 15% Ownership Interest through the issuance of an additional 3,000,000 Shares to GCL on or before the third anniversary of the Execution Date.
		g)	In the event the Effective Date does not occur within twelve (12) months from the Execution Date:
		(i)	GCL shall return all Shares issued to it by Enertopia pursuant to this Agreement other than 3,600,000 Shares of the 10,000,000 Shares issued pursuant to the term of GCL Agreement (comprised of 1,800,000 Shares issued to Wolverton Securities and 1,800,000 Shares issued to GCL) which GCL shall be entitled to retain;
		(ii)	The Management Agreements (as hereinafter defined) shall terminate immediately and Enertopia shall have no further obligation with respect to the Management Compensation (as hereinafter defined); and
		(iii)	This Agreement shall terminate and Enertopia will be released from all obligations under this GCL Agreement and GCL will also be so released provided that it has fulfilled its obligation pursuant to the term of GCL Agreement
	The terms of the GCL Agreement also require Enertopia to fund, for a period of three years subject to early termination of the Agreement, any shortfall in the payment of management fees to certain Green Canvas consultants in the amount of $15,000 per month, which fees are to be paid out of the gross profits of the GCL Business.
	The parties did not form a separate legal entity as part of the GCL Agreement; therefore, the Company accounts for the GCL Agreement as a collaborative arrangement in accordance with applicable accounting guidance. As at February 28, 2015, the Company also recorded restricted common shares issued to GCL for total amount of $384,000 as assets (August 31, 2014: $768,000). As at February 28, 2015, the Company expensed $384,000 due to the decrease in share value related to the agreement.
	(c)	On March 5, 2014, the Company and Mr. Robert McAllister has entered into a three year Joint Venture Agreement ("JV") with Lexaria Corp. (collectively, the "Parties"). Whereas the Company and Robert McAllister will source opportunities in the business, and the terms and conditions on which the Parties will form a joint venture to jointly participate in, or offer specific opportunities within the business (the "Joint Venture"), and Robert McAllister will join the Lexaria Corp. advisory board for the term of this Agreement. Lexaria Corp. issued the Company 1,000,000 shares and Robert McAllister 500,000 shares upon signing of the Agreement. Lexaria agrees to additionally pay Enertopia a finder’s commission, received at the sole election of Enertopia in either cash or in common restricted shares of Lexaria, within a range of 2% - 5% of the value (less of taxes) of any future business acquisition, joint venture or transaction that Lexaria accepts and closes for the life of this Agreement. Lexaria as its initial Contribution, hereby pays to McAllister 500,000 common restricted shares as compensation for entering the Joint Venture and for McAllister to initiate and during the term of the Agreement continue to provide to Lexaria opportunities for Lexaria to build its business. Lexaria agrees to additionally award McAllister 500,000 stock options to buy common shares of Lexaria, with terms to be specified and ratified by shareholder and regulatory approvals, as compensation for joining and serving as Chairperson of Lexaria’s marijuana business advisory board for the term of this Agreement.
	(d)	On May 28, 2014, Enertopia and Lexaria signed a Definitive Agreement. Enertopia and Lexaria each wish to develop a business of legally producing, manufacturing, propagating, importing/exporting, testing, researching and developing, marijuana (the "Business") located in Ontario (the "Property"), and on or about April 10, 2014, the Parties entered a Letter of Intent that set forth the basic terms of a proposed joint venture agreement between Enertopia and Lexaria for those purposes. Lexaria issued 500,000 common shares to Enertopia. Enertopia wishes to acquire a license from Health Canada to designate Enertopia as a Licensed Producer pursuant to Canada's Marijuana for Medical Purposes Regulations (the "License"). The Parties are entering into this Agreement to set out the terms and conditions by which Enertopia does own a 51% interest in the Business and Lexaria does own a 49% interest in the Business; and the terms and conditions on which the Parties will form and operate the joint venture to jointly participate in the Business (the "Joint Venture").
	The Parties contribute the following as their initial contributions to the Business:
	Enertopia, as its initial contribution, hereby contributes $45,000 to the Joint Venture bank account. Lexaria, as its initial contribution, hereby contributes $55,000 to the Joint Venture bank account.
	The Parties shall have the following Ownership Interests under this Agreement and of the Business:
	Enertopia          - 51%
	Lexaria               - 49%
	The Parties shall bear the costs arising under this Agreement and the operation of the Business as to the following, as further described in this Agreement (the “Cost Interests”):
	Enertopia            - 45%
	Lexaria                - 55%
	The Parties shall have the following insured liability for all things that are not operating costs arising under this Agreement and the operation of the Business as to the following:
	Enertopia - 51%
	Lexaria                 - 49%
	The Parties shall receive all revenues and profits derived from the operation of the Business as to the following, as further described in this Agreement (the “Revenue Interests”):
	Enertopia - 51%
	Lexaria                 - 49%
	Enertopia shall act as the manager of the Operations (the "Manager") for so long as its Ownership Interest is 51% or more. Enertopia may designate a specified individual as Manager if the Parties unanimously consent to such appointment. If any party, including Lexaria, gains a 51% Ownership Interest in the Business, then Enertopia shall have the obligation, if requested by the 51% Ownership Interest party, to surrender the Manager position.
	The parties did not form a separate legal entity as part of the Joint Venture Agreement; therefore, the Company accounts for the Joint Venture as a collaborative arrangement in accordance with ASC 808 “ Collaborative Arrangements ”. During the year ended August 31, 2014, the Company recorded $9,250 as expenses related to the collaborative arrangement. The Company also recorded leasehold improvement of $6,271 as assets. As at February 28, 2015, the Company recorded $9,838 in expenses relating to the agreement.

SEXUAL_ENHANCEMENT_GEL

SEXUAL ENHANCEMENT GEL	6 Months Ended
	Feb. 28, 2015
SEXUAL ENHANCEMENT GEL [Text Block]	7	SEXUAL ENHANCEMENT GEL
	On February 9, 2015, Enertopia announced the launch of a new product line V-Love TM for women’s sexual health. V-Love TM for women is a sexual stimulatory gel that provides sensation to assist women with desire. The gel is currently under production and will be available for sale in Canada during the third quarter and for sale in the USA in the fourth quarter. Enertopia owns 100% of the product and its formulation. Enertopia engaged a laboratory in Vancouver to formulate the final ingredients for V-Love TM and for the production of the sexual desire gel.
	As at Feburary 28, 2015, the Company has recorded inventory of $17,864 relating to V-Love sample products and expensed $5,364 research and development costs.

RELATED_PARTIES_TRANSACTION

RELATED PARTIES TRANSACTION	6 Months Ended
	Feb. 28, 2015
RELATED PARTIES TRANSACTION [Text Block]	8	RELATED PARTIES TRANSACTION
	For the six months ended February 28, 2015, the Company was party to the following related party transactions:
		•	Paid/accrued $39,000 (February 28, 2014: $30,000) to the President of the Company in consulting fees.
		•	Paid/accrued $45,000 CAD (February 28, 2014: $33,000 CAD) in consulting fees to a company controlled by the CFO of the Company.
		•	$65,750 was payable to the President and a company controlled by a CFO of the Company.
		•	Incurred share based compensation expenses of $103,111 in relation to stock options issued to key management personnel (February 28, 2014: $nil).
		•	See Note 6.
	The related party transactions are recorded at the exchange amount established and agreed to between the related parties.

COMMON_STOCK

COMMON STOCK	6 Months Ended
	Feb. 28, 2015
COMMON STOCK [Text Block]	9	COMMON STOCK
	On April 24, 2014 the Company entered into a one year consulting contract with 2342878 Ontario Inc. wholly owned company by Chris Hornung as Assistant Operations Manager. Upon signing of the contract of acceptance the Company issued 90,000 common shares at a deemed price of $0.34. Based on the milestones listed in the contract, Mr. Hornung or his company can be eligible to receive up to a total of 472,500 common shares of the Company. In July, the Company accepted Mr. Hornung’s resignation. The 90,000 common shares of the Company that were issued have been returned back to treasury on September 24, 2014.
	On October 16, 2014 the Company entered into a termination and settlement agreement, dated effective October 14, 2014, with WOM and Mathew Chadwick (the “Settlement Agreement ”), pursuant to which the parties have entered into mutual releases, Mr. Chadwick has resigned from the Company’s board of directors and as an officer of the company, and WOM has returned back to the treasury of the company 15,127,287 common shares that had been issued to it. Given the foregoing, all relationships between the parties, including but not limited to the WOM Agreement in regards to the Joint Venture business, have been terminated.
	On January 30, 2015, the Company closed the first tranche of a private placement of 1,665,000 untis at a price of CAD$0.06 per unit for gross proceeds of CAD$99,900. Each unit consists of one common share of the Company and one non-transferable share purchase warrant, each full warrant entitling the holder to purchase one additional common share of the Company for a period of 36 months from the date of issuance, at a purchase price of US$0.10 during the first 24 months and at US$0.15 after 24 months. A cash finders’ fee of CAD$7,358 and 122,640 full broker warrants that expire on January 30, 2018 was paid to Canaccord Genuity.
	As at February 28, 2015, the Company had 77,318,460 shares issued and outstanding.

STOCK_OPTIONS_AND_WARRANTS

STOCK OPTIONS AND WARRANTS	6 Months Ended
	Feb. 28, 2015
STOCK OPTIONS AND WARRANTS [Text Block]	10	STOCK OPTIONS AND WARRANTS
	Stock Options
	On July 15, 2014, the shareholders approved and adopted at the Annual General Meeting the Company’s 2014 Stock Option Plan. On April 14, 2011, the shareholders approved and adopted at the Annual General Meeting to consolidate the Company’s 2007 Equity compensation plan and the Company’s 2010 Equity Compensation Plan into a new Company 2011 Stock Option Plan. The purpose of these Plans is to advance the interests of the Corporation, through the grant of Options, by providing an incentive mechanism to foster the interest of eligible persons in the success of the Corporation and its affiliates; encouraging eligible persons to remain with the Corporation or its affiliates; and attracting new Directors, Officers, Employees and Consultants.
	On November 3, 2014 the Company granted 2,100,000 stock options to directors, officers, and consultant of the Company with an exercise price of $0.10 vested immediately, expiring November 3, 2019.
	On November 18, 2014, the Company granted 100,000 stock options to consultant of the Company with an exercise price of $0.10 vested immediately, expiring November 13, 2019.
	For the six months ended February 28, 2015, the Company recorded $177,595 (February 28, 2014 – $92,029) stock based compensation expenses which has been included in consulting fees.
	A summary of the changes in stock options for the six months ended February 28, 2015 is presented below:
							Options Outstanding
							Weighted Average
				Number of Shares			Exercise Price
		Balance, August 31, 2014		3,655,000		$	0.33
		Cancelled		(550,000	)		0.07 – 0.86
		Expired		(700,000	)		0.1
		Granted		2,200,000			0.1
		Balance, February 28, 2015		4,605,000		$	0.18
	The fair value of options granted has been estimated as of the date of the grant by using the Black-Scholes option pricing model with the following assumptions:
				28-Feb-15			31-Aug-14
		Expected volatility		216% - 219%			204% - 219%
		Risk-free interest rate		1.63% - 1.79%			1.33% - 1.79%
		Expected life		5.00 years			5.00 years
		Dividend yield		0.00%			0.00%
		Estimated fair value per option	$	0.06 - $0.07		$	0.05 - $0.69
	The Company has the following options outstanding and exercisable.
		28-Feb-15					Options outstanding			Options exercisable
				Number			Remaining		Exercise	Number		Exercise
		Exercise prices		of shares			contractual		Price	of shares		Price
							life			exercisable
		$0.10		100,000			4.72 years	$	0.1	100,000	$	0.1
		$0.10		2,100,000			4.68 years	$	0.1	2,100,000	$	0.1
		$0.50		50,000			4.10 years	$	0.5	50,000	$	0.5
		$0.70		500,000			4.07 years	$	0.7	250,000	$	0.7
		$0.35		50,000			3.93 years	$	0.35	25,000	$	0.35
		$0.16		250,000			3.87 years	$	0.16	250,000	$	0.16
		$0.06		550,000			3.68 years	$	0.06	550,000	$	0.06
		$0.15		555,000			0.96 years	$	0.15	555,000	$	0.15
		$0.15		150,000			1.02 years	$	0.15	150,000	$	0.15
		$0.15		150,000			2.05 years	$	0.15	150,000	$	0.15
		$0.20		100,000			0.69 years	$	0.2	100,000	$	0.2
		$0.25		50,000			1.25 years	$	0.25	50,000	$	0.25
				4,605,000			3.66 years	$	0.18	4,605,000	$	0.18
							Options outstanding					Options exercisable
		31-Aug-14
				Number			Remaining		Exercise	Number		Remaining		Exercise
		Exercise prices		of shares			contractual		Price	of shares		contractual		Price
							life			exercisable		life
		$0.50		50,000			4.60 years	$	0.5	50,000		4.60 years	$	0.5
		$0.72		100,000			4.59 years	$	0.72	100,000		4.59 years	$	0.72
		$0.86		200,000			4.58 years	$	0.86	200,000		4.58 years	$	0.86
		$0.70		500,000			4.57 years	$	0.7	250,000		4.57 years	$	0.7
		$0.68		200,000			4.53 years	$	0.68	100,000		4.53 years	$	0.68
		$0.35		50,000			4.43 years	$	0.35	50,000		4.43 years	$	0.35
		$0.16		250,000			4.37 years	$	0.16	250,000		4.37 years	$	0.16
		$0.08		50,000			4.34 years	$	0.075	50,000		4.34 years	$	0.075
		$0.06		550,000			4.18 years	$	0.06	550,000		4.18 years	$	0.06
		$0.10		300,000			0.14 years	$	0.1	300,000		0.14 years	$	0.1
		$0.10		400,000			0.33 years	$	0.1	400,000		0.33 years	$	0.1
		$0.15		555,000			1.45 years	$	0.15	555,000		1.45 years	$	0.15
		$0.15		150,000			1.52 years	$	0.15	150,000		1.52 years	$	0.15
		$0.15		150,000			2.55 years	$	0.15	150,000		2.55 years	$	0.15
		$0.20		100,000			1.19 years	$	0.2	100,000		1.19 years	$	0.2
		$0.25		50,000			1.75 years	$	0.25	50,000		1.75 years	$	0.25
				3,655,000			2.85 years	$	0.3	3,305,000		2.67 years	$	0.25
	Warrants
	A summary of warrants as at February 28, 2015 and August 31, 2014 is as follows:
						Warrant Outstanding
						Weighted Average
			Number of warrant			Exercise Price
	Balance, August 31, 2014		13,606,245		$	0.14
	Granted		1,787,640			0.1
	Balance, February 28, 2015		15,393,885		$	0.14
	Number		Exercise			Expiry
	Outstanding 1		Price			Date
	460,000	$	0.2			27-Jul-15
	136,000	$	0.2			24-Aug-15
	278,275	$	0.2			28-Sep-15
	430,670	$	0.2			15-Nov-15
	1,468,000	$	0.1			26-Nov-16
	1,438,800	$	0.1			23-Dec-16
	2,167,160	$	0.15			31-Jan-16
	7,227,340	$	0.15			13-Feb-16
	1,787,640	$	0.10 and $0.15 after 24 months			30-Jan-18
	15,393,885
1. Each warrant entitles a holder to purchase one common share.

COMMITMENTS_OTHER

COMMITMENTS OTHER	6 Months Ended
	Feb. 28, 2015
COMMITMENTS OTHER [Text Block]	11	COMMITMENTS – OTHER
		(a)	The Company has a consulting agreement with the President of the Company for corporate administration and consulting services for $5,000 per month plus HST/GST on a continuing basis. Effective March 1, 2014, the Company entered into a new consulting contract with the consulting services at $6,500 per month plus GST.
		(b)	On October 9, 2009, the Company entered into consulting agreement with BKB Management Ltd., a corporation organized under the laws of the Province of British Columbia. BKB Management Ltd. is a consulting company controlled by the chief financial officer of the Company. BKB Management provides management consulting services for CAD$4,500 per month plus HST/GST. Effective April 1, 2011, the consulting services are CAD$5,500 per month plus HST/GST. Effective March 1, 2014, the Company entered into a new consulting agreement with the consulting services at CAD$7,500 per month plus GST.
		(c)	On January 13, 2014, the Company entered into a corporate development agreement with Don Shaxon. The initial term of this agreement shall begin on the date of execution of this agreement and continue for twelve months. Thereafter the agreement will continue on a month-by-month basis pending cancelation by written notification with 30 days notice. In consideration for the services the Company will pay the Provider Don Shaxon a signing stock bonus of 250,000 common shares of the Company, one-time cash bonus of $40,000 90 days after the commencement of the contract, and a monthly fee of $3,500 plus $500 in monthly expenses. Upon execution of the Agreement, the Company also granted 250,000 stock options. to Don Shaxon with respect to the corporate development agreement dated January 13, 2014. The exercise price of the stock options is $0.16, 250,000 stock options vested immediately, expiring January 13, 2019. On May 5, 2014, the Company signed an Addendum with Don Shaxon. The monthly compensation increased to $7,500 including expenses.
		(d)	On February 27, 2014, the Company signed a $50,000 12 month marketing agreement with Agoracom payable in common shares of the Company on a quarterly basis. The first quarter payment of $12,500 has been paid by issuing 54,347 common shares of the Company at a market price of $0.23 per share. On June 9, 2014, the Company made its second quarterly payment by issuing 72,917 common shares of the Company at a market price of $0.18 per share.
		(e)	On April 24, 2014, the Company entered into a one year consulting contract with Clark Kent as Media Coordinator for a monthly fee of CAD$2,250 plus GST. Upon signing of the contract of acceptance the Company issued 90,000 common shares. Based on the milestones listed in the contract, Mr. Kent can be eligible to receive up to a total of 472,500 common shares of the Company.
		(f)	On April 24, 2014, the Company entered into a one year consulting contract with Don Shaxon as Ontario Operations Manager for a monthly fee of CAD$3,375 plus GST. Upon signing of the contract of acceptance the Company issued 90,000 common shares. Based on the milestones listed in the contract, Mr. Shaxon can be eligible to receive up to a total of 472,500 common shares of the Company.
		(g)	On April 24, 2014, the Company entered into a one year consulting contract with 490072 Ontario Ltd. operating as HEC Group, wholly owned company by Greg Boone as Human Resources Manager. Upon signing of the contract of acceptance the Company issued 90,000 common shares. Based on the milestones listed in the contract, Mr. Boone or his company can be eligible to receive up to a total of 472,500 common shares of the Company.
		(h)	On April 24, 2014, the Company entered into a one year consulting contract with Jason Springett as Master Grower for Ontario Operations for a monthly fee of $3,375 plus GST. Upon signing of the contract of acceptance the Company issued 90,000 common shares. Based on the milestones listed in the contract, Mr. Springett can be eligible to receive up to a total of 472,500 common shares of the Company.
		(i)	On July 1, 2014, the Company has entered into a one year services agreement with TDM Financial for $120,000 payable in common shares of the Company. TDM Financial will provide marketing solutions and strategies to the Company. Upon the signing of the contract with TDM Financial, the Company issued 750,000 common stock of the Company at a deemed price of $0.16 for the term of the agreement.
		(j)	On August 1, 2014, the Company signed an extension to the Letter of intent executed on April 10, 2014 on behalf of a corporation to be incorporated by Lexaria Corp. and Enertopia Corporation (Lessee) and Mr. Jeff Paikin of 1475714 Ontario Inc. (Lessor) sets out the Lessee’s and Lessor’s shared intent to enter into a lease agreement (the “Lease”) for warehouse space (the “Leased Premises”) in the building located at Burlington, Ontario (the “Building”). On August 5, 2014, as per the terms of the extension, 118,416 common shares of the Company were issued at a deemed price of $0.19 per share. On December 12, 2014, the Company signed an extension on an amended Preliminary Lease Agreement and Extension of LOI, that was first executed on April 10, 2014 on behalf of Lexaria CanPharm Corp. - a wholly owned subsidiary of Lexaria, and Enertopia Corporation(Lessee) and Mr. Jeff Paikin of 1475714 Ontario Inc. (Lessor) sets out the Lessee’s and Lessor’s shared intent to enter into a lease agreement (the “Lease”) for warehouse space (the “Leased Premises”) in the building located at Burlington, Ontario (the “Building”) with Enertopia’s monthly portion being $6,992.
		(k)	On August 1, 2014, the Company entered into a three month Investor Relations and Marketing Agreement with Neil Blake with a monthly fee of CAD$2,500. The agreement is extended on a month-to-month basis.
		(l)	On September 18, 2014, the Company entered into a contract with the Company’s joint venture partner Lexaria Corp., and Maureen McGrath pursuant to which Ms. McGrath will lead the National Medical Marijuana Awareness and Outreach Strategy, a public awareness program jointly administered by Lexaria and our company.
		(m)	On February 9, 2015, the Company entered into a one year contract with Maureen McGrath/McGrath Group as Lead Medical Strategist, with a monthly fee of CAD$3,000.
		(n)	Also see note 7.

SEGMENTED_INFORMATION

SEGMENTED INFORMATION	6 Months Ended
	Feb. 28, 2015
SEGMENTED INFORMATION [Text Block]	12	SEGMENTED INFORMATION
	The Company identifies its segments based on the way management organizes the Company to assess performance and make operating decisions regarding the allocation of resources. In accordance with the criteria in FASB ASC 280 " Segment Reporting ," the Company has concluded it has two reportable segments: renewable energy, and oil and gas, and medical marijuana, which are managed separately based on fundamental differences in their operations nature.
	Summarized financial information concerning the Company’s reportable segments is shown in the following tables:
				Renewable
		Quarter ended February 28, 2015		Energy		Medical Marijuana			Corporate			Consolidated
		Revenues	$	-	$	-		$	-		$	-
		Net income (loss) from operations		-		(394,001	)		(907,653	)		(1,301,654	)
		Total assets	$	1	$	390,272		$	807,333		$	1,197,606
	The operations of the Group are located geographically in the Canada.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Feb. 28, 2015
SUBSEQUENT EVENTS [Text Block]	13	SUBSEQUENT EVENTS
		(a)	On March 12, 2015, the Company closed the final tranche of a private placement of 590,000 units at a price of CAD$0.06 per unit for gross proceeds of CAD$35,400. Each unit consists of one common share of the Company and one non-transferable share purchase warrant, each full warrant entitling the holder to purchase one additional common share of the Company for a period of 36 months from the date of issuance, at a purchase price of US$0.10 during the first 24 months and at US$0.15 after 24 months. A cash finders’ fee of CAD$2,832 and 47,200 full broker warrants that expire on March 12, 2018 was paid to Canaccord Genuity.

COMPARATIVE_INFORMATION

COMPARATIVE INFORMATION	6 Months Ended
	Feb. 28, 2015
COMPARATIVE INFORMATION [Text Block]	14	COMPARATIVE INFORMATION
	Certain comparative information has been reclassified to conform with the presentation adopted in the current period.

Summary_of_Significant_Account

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Feb. 28, 2015
Basis of Consolidation [Policy Text Block]	a)	Basis of Consolidation
	The unaudited interim consolidated financial statements include the financial statements of the Company and its wholly-owned subsidiaries, Thor Pharma Corp. and Target Energy, Inc. Target Energy, Inc. was dissolved effective November 4, 2013 with no significant accounting impact. The unaudited interim consolidated financial statements also include the equity interests of Global Solar Water Power Systems Inc. Global Solar Water Power Systems Inc. has been written down to $1. All significant inter-company balances and transactions have been eliminated.
New Accounting Pronouncements [Policy Text Block]	b)	New Accounting Pronouncements
	FASB ASU 2014-09, “Revenue from Contracts with Customers,” was issued May 2014 and updates the principles for recognizing revenue. The ASU will supersede most of the existing revenue recognition requirements in U.S. GAAP and will require entities to recognize revenue at an amount that reflects the consideration to which the Company expects to be entitled in exchange for transferring goods or services to a customer. This ASU also amends the required disclosures of the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The guidance is effective for annual periods beginning after December 15, 2016, including interim periods within that period. Early adoption is not permitted under U.S. GAAP. The Company is determining its implementation approach and evaluating the potential impacts of the new standard on its existing revenue recognition policies and procedures.
	FASB ASU 2014-12, “Compensation - Stock Compensation (Topic 718), Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period,” was issued June 2014. This guidance was issued to resolve diversity in accounting for performance targets. A performance target in a share-based payment that affects vesting and that could be achieved after the requisite service period should be accounted for as a performance condition and should not be reflected in the award’s grant date fair value. Compensation cost should be recognized over the required service period, if it is probable that the performance condition will be achieved. The guidance is effective for annual periods beginning after December 15, 2015 and interim periods within those annual periods. The Company does not anticipate a significant impact upon adoption.
	FASB ASU 2014-15, “Presentation of Financial Statements-Going Concern (Subtopic 205-40) Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” which was issued September 2014. This provides guidance on determining when and how to disclose going-concern uncertainties in the financial statements. The new standard requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date the financial statements are issued. An entity must provide certain disclosures if conditions or events raise substantial doubt about the entity’s ability to continue as a going concern. The ASU applies to all entities and is effective for annual periods ending after December 15, 2016, and interim periods thereafter, with early adoption permitted. The Company does not anticipate a significant impact upon adoption.
	Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s financial statements upon adoption.

STOCK_OPTIONS_AND_WARRANTS_Tab

STOCK OPTIONS AND WARRANTS (Tables)	6 Months Ended												12 Months Ended
	Feb. 28, 2015												Aug. 31, 2014
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]							Options Outstanding
							Weighted Average
				Number of Shares			Exercise Price
		Balance, August 31, 2014		3,655,000		$	0.33
		Cancelled		(550,000	)		0.07 – 0.86
		Expired		(700,000	)		0.1
		Granted		2,200,000			0.1
		Balance, February 28, 2015		4,605,000		$	0.18
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]				28-Feb-15			31-Aug-14
		Expected volatility		216% - 219%			204% - 219%
		Risk-free interest rate		1.63% - 1.79%			1.33% - 1.79%
		Expected life		5.00 years			5.00 years
		Dividend yield		0.00%			0.00%
		Estimated fair value per option	$	0.06 - $0.07		$	0.05 - $0.69
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]		28-Feb-15					Options outstanding			Options exercisable						Options outstanding				Options exercisable
				Number			Remaining		Exercise	Number		Exercise		31-Aug-14
		Exercise prices		of shares			contractual		Price	of shares		Price			Number	Remaining		Exercise	Number	Remaining		Exercise
							life			exercisable				Exercise prices	of shares	contractual		Price	of shares	contractual		Price
		$0.10		100,000			4.72 years	$	0.1	100,000	$	0.1				life			exercisable	life
		$0.10		2,100,000			4.68 years	$	0.1	2,100,000	$	0.1		$0.50	50,000	4.60 years	$	0.5	50,000	4.60 years	$	0.5
		$0.50		50,000			4.10 years	$	0.5	50,000	$	0.5		$0.72	100,000	4.59 years	$	0.72	100,000	4.59 years	$	0.72
		$0.70		500,000			4.07 years	$	0.7	250,000	$	0.7		$0.86	200,000	4.58 years	$	0.86	200,000	4.58 years	$	0.86
		$0.35		50,000			3.93 years	$	0.35	25,000	$	0.35		$0.70	500,000	4.57 years	$	0.7	250,000	4.57 years	$	0.7
		$0.16		250,000			3.87 years	$	0.16	250,000	$	0.16		$0.68	200,000	4.53 years	$	0.68	100,000	4.53 years	$	0.68
		$0.06		550,000			3.68 years	$	0.06	550,000	$	0.06		$0.35	50,000	4.43 years	$	0.35	50,000	4.43 years	$	0.35
		$0.15		555,000			0.96 years	$	0.15	555,000	$	0.15		$0.16	250,000	4.37 years	$	0.16	250,000	4.37 years	$	0.16
		$0.15		150,000			1.02 years	$	0.15	150,000	$	0.15		$0.08	50,000	4.34 years	$	0.075	50,000	4.34 years	$	0.075
		$0.15		150,000			2.05 years	$	0.15	150,000	$	0.15		$0.06	550,000	4.18 years	$	0.06	550,000	4.18 years	$	0.06
		$0.20		100,000			0.69 years	$	0.2	100,000	$	0.2		$0.10	300,000	0.14 years	$	0.1	300,000	0.14 years	$	0.1
		$0.25		50,000			1.25 years	$	0.25	50,000	$	0.25		$0.10	400,000	0.33 years	$	0.1	400,000	0.33 years	$	0.1
														$0.15	555,000	1.45 years	$	0.15	555,000	1.45 years	$	0.15
				4,605,000			3.66 years	$	0.18	4,605,000	$	0.18		$0.15	150,000	1.52 years	$	0.15	150,000	1.52 years	$	0.15
														$0.15	150,000	2.55 years	$	0.15	150,000	2.55 years	$	0.15
														$0.20	100,000	1.19 years	$	0.2	100,000	1.19 years	$	0.2
														$0.25	50,000	1.75 years	$	0.25	50,000	1.75 years	$	0.25
															3,655,000	2.85 years	$	0.3	3,305,000	2.67 years	$	0.25
Schedule of Stockholders' Equity Note, Warrants or Rights, Activity [Table Text Block]							Warrant Outstanding
							Weighted Average
				Number of warrant			Exercise Price
		Balance, August 31, 2014		13,606,245		$	0.14
		Granted		1,787,640			0.1
		Balance, February 28, 2015		15,393,885		$	0.14
Schedule of Share Based Payment Award Equity Note Warrants or Rights Valuation Assumptions [Table Text Block]		Number		Exercise			Expiry
		Outstanding 1		Price			Date
		460,000	$	0.2			27-Jul-15
		136,000	$	0.2			24-Aug-15
		278,275	$	0.2			28-Sep-15
		430,670	$	0.2			15-Nov-15
		1,468,000	$	0.1			26-Nov-16
		1,438,800	$	0.1			23-Dec-16
		2,167,160	$	0.15			31-Jan-16
		7,227,340	$	0.15			13-Feb-16
		1,787,640	$	0.10 and $0.15 after 24 months			30-Jan-18
		15,393,885

SEGMENTED_INFORMATION_Tables

SEGMENTED INFORMATION (Tables)	6 Months Ended
	Feb. 28, 2015
Schedule of Segment Reporting Information, by Segment [Table Text Block]				Renewable
		Quarter ended February 28, 2015		Energy		Medical Marijuana			Corporate			Consolidated
		Revenues	$	-	$	-		$	-		$	-
		Net income (loss) from operations		-		(394,001	)		(907,653	)		(1,301,654	)
		Total assets	$	1	$	390,272		$	807,333		$	1,197,606

ORGANIZATION_Narrative_Details

ORGANIZATION (Narrative) (Details)	6 Months Ended
	Feb. 28, 2015
Organization 1	200,000,000

GOING_CONCERN_UNCERTAINTY_Narr

GOING CONCERN UNCERTAINTY (Narrative) (Details) (USD $)	6 Months Ended
	Feb. 28, 2015
Going Concern Uncertainty 1	$1,301,654
Going Concern Uncertainty 2	472,213
Going Concern Uncertainty 3	$12,067,317

SIGNIFICANT_ACCOUNTING_POLICIE1

SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) (USD $)	6 Months Ended
	Feb. 28, 2015
Significant Accounting Policies 1	$1

OWNED_SECURITIES_Narrative_Det

OWNED SECURITIES (Narrative) (Details) (USD $)	6 Months Ended
	Feb. 28, 2015
	M
Owned Securities 1	375,000
Owned Securities 2	$0.01
Owned Securities 3	$0.01
Owned Securities 4	1,000,000
Owned Securities 5	$0.09
Owned Securities 6	500,000
Owned Securities 7	$0.40
Owned Securities 8	24

LONG_TERM_INVESTMENTS_Narrativ

LONG TERM INVESTMENTS (Narrative) (Details) (USD $)	6 Months Ended
	Feb. 28, 2015
Long Term Investments 1	20.00%
Long Term Investments 2	$1

MEDICAL_MARIJUANA_INVESTMENT_N

MEDICAL MARIJUANA INVESTMENT (Narrative) (Details) (USD $)	6 Months Ended
	Feb. 28, 2015
Medical Marijuana Investment 1	51.00%
Medical Marijuana Investment 2	51.00%
Medical Marijuana Investment 3	10,000,000
Medical Marijuana Investment 4	5,000,000
Medical Marijuana Investment 5	98
Medical Marijuana Investment 6	$100,000
Medical Marijuana Investment 7	75,000
Medical Marijuana Investment 8	30.00%
Medical Marijuana Investment 9	1,000,000
Medical Marijuana Investment 10	98
Medical Marijuana Investment 11	200,000
Medical Marijuana Investment 12	1.00%
Medical Marijuana Investment 13	1,000,000
Medical Marijuana Investment 14	98
Medical Marijuana Investment 15	200,000
Medical Marijuana Investment 16	2.00%
Medical Marijuana Investment 17	1,000,000
Medical Marijuana Investment 18	98
Medical Marijuana Investment 19	200,000
Medical Marijuana Investment 20	6.00%
Medical Marijuana Investment 21	1,000,000
Medical Marijuana Investment 22	98
Medical Marijuana Investment 23	300,000
Medical Marijuana Investment 24	6.00%
Medical Marijuana Investment 25	1,000,000
Medical Marijuana Investment 26	98
Medical Marijuana Investment 27	300,000
Medical Marijuana Investment 28	6.00%
Medical Marijuana Investment 29	51.00%
Medical Marijuana Investment 30	375,000
Medical Marijuana Investment 31	375,000
Medical Marijuana Investment 32	375,000
Medical Marijuana Investment 33	15,127,287
Medical Marijuana Investment 34	392,454
Medical Marijuana Investment 35	75.00%
Medical Marijuana Investment 36	75.00%
Medical Marijuana Investment 37	100,000
Medical Marijuana Investment 38	49.00%
Medical Marijuana Investment 39	10,000,000
Medical Marijuana Investment 40	500,000
Medical Marijuana Investment 41	113,400
Medical Marijuana Investment 42	6,400,000
Medical Marijuana Investment 43	250,000
Medical Marijuana Investment 44	3,000,000
Medical Marijuana Investment 45	2.00%
Medical Marijuana Investment 46	51.00%
Medical Marijuana Investment 47	150,000
Medical Marijuana Investment 48	3,000,000
Medical Marijuana Investment 49	9.00%
Medical Marijuana Investment 50	60.00%
Medical Marijuana Investment 51	60.00%
Medical Marijuana Investment 52	15.00%
Medical Marijuana Investment 53	3,000,000
Medical Marijuana Investment 54	3,600,000
Medical Marijuana Investment 55	10,000,000
Medical Marijuana Investment 56	1,800,000
Medical Marijuana Investment 57	1,800,000
Medical Marijuana Investment 58	15,000
Medical Marijuana Investment 59	384,000
Medical Marijuana Investment 60	768,000
Medical Marijuana Investment 61	384,000
Medical Marijuana Investment 62	1,000,000
Medical Marijuana Investment 63	500,000
Medical Marijuana Investment 64	2.00%
Medical Marijuana Investment 65	5.00%
Medical Marijuana Investment 66	500,000
Medical Marijuana Investment 67	500,000
Medical Marijuana Investment 68	500,000
Medical Marijuana Investment 69	51.00%
Medical Marijuana Investment 70	49.00%
Medical Marijuana Investment 71	45,000
Medical Marijuana Investment 72	55,000
Medical Marijuana Investment 73	51.00%
Medical Marijuana Investment 74	49.00%
Medical Marijuana Investment 75	45.00%
Medical Marijuana Investment 76	55.00%
Medical Marijuana Investment 77	51.00%
Medical Marijuana Investment 78	49.00%
Medical Marijuana Investment 79	51.00%
Medical Marijuana Investment 80	49.00%
Medical Marijuana Investment 81	51.00%
Medical Marijuana Investment 82	51.00%
Medical Marijuana Investment 83	51.00%
Medical Marijuana Investment 84	9,250
Medical Marijuana Investment 85	6,271
Medical Marijuana Investment 86	$9,838

SEXUAL_ENHANCEMENT_GEL_Narrati

SEXUAL ENHANCEMENT GEL (Narrative) (Details) (USD $)	6 Months Ended
	Feb. 28, 2015
Sexual Enhancement Gel 1	100.00%
Sexual Enhancement Gel 2	$17,864
Sexual Enhancement Gel 3	$5,364

RELATED_PARTIES_TRANSACTION_Na

RELATED PARTIES TRANSACTION (Narrative) (Details) (USD $)	6 Months Ended
	Feb. 28, 2015
Related Parties Transaction 1	$39,000
Related Parties Transaction 2	30,000
Related Parties Transaction 3	45,000
Related Parties Transaction 4	33,000
Related Parties Transaction 5	65,750
Related Parties Transaction 6	103,111
Related Parties Transaction 7	$0

COMMON_STOCK_Narrative_Details

COMMON STOCK (Narrative) (Details)	6 Months Ended
	Feb. 28, 2015	Feb. 28, 2015
	USD ($)	CAD
	M
Common Stock 1	90,000	90,000
Common Stock 2	$0.34
Common Stock 3	472,500	472,500
Common Stock 4	90,000	90,000
Common Stock 5	15,127,287	15,127,287
Common Stock 6	1,665,000	1,665,000
Common Stock 7		0.06
Common Stock 8		99,900
Common Stock 9	36	36
Common Stock 10	0.1
Common Stock 11	24	24
Common Stock 12	0.15
Common Stock 13	24	24
Common Stock 14		7,358
Common Stock 15	122,640	122,640
Common Stock 16	77,318,460	77,318,460

STOCK_OPTIONS_AND_WARRANTS_Nar

STOCK OPTIONS AND WARRANTS (Narrative) (Details) (USD $)	6 Months Ended
	Feb. 28, 2015
Stock Options And Warrants 1	2,100,000
Stock Options And Warrants 2	$0.10
Stock Options And Warrants 3	100,000
Stock Options And Warrants 4	0.1
Stock Options And Warrants 5	177,595
Stock Options And Warrants 6	$92,029

COMMITMENTS_OTHER_Narrative_De

COMMITMENTS OTHER (Narrative) (Details)	6 Months Ended
	Feb. 28, 2015	Feb. 28, 2015
	USD ($)	CAD
	M
	D
Commitments Other 1	5,000	5,000
Commitments Other 2	6,500	6,500
Commitments Other 3	4,500	4,500
Commitments Other 4	5,500	5,500
Commitments Other 5	7,500	7,500
Commitments Other 6	30	30
Commitments Other 7	250,000	250,000
Commitments Other 8	$40,000
Commitments Other 9	90	90
Commitments Other 10	3,500
Commitments Other 11	500
Commitments Other 12	250,000	250,000
Commitments Other 13	0.16
Commitments Other 14	250,000	250,000
Commitments Other 15	7,500
Commitments Other 16	50,000
Commitments Other 17	12	12
Commitments Other 18	12,500
Commitments Other 19	54,347	54,347
Commitments Other 20	$0.23
Commitments Other 21	72,917	72,917
Commitments Other 22	$0.18
Commitments Other 23		2,250
Commitments Other 24	90,000	90,000
Commitments Other 25	472,500	472,500
Commitments Other 26		3,375
Commitments Other 27	90,000	90,000
Commitments Other 28	472,500	472,500
Commitments Other 29	490,072	490,072
Commitments Other 30	90,000	90,000
Commitments Other 31	472,500	472,500
Commitments Other 32	3,375
Commitments Other 33	90,000	90,000
Commitments Other 34	472,500	472,500
Commitments Other 35	120,000
Commitments Other 36	750,000	750,000
Commitments Other 37	0.16
Commitments Other 38	118,416	118,416
Commitments Other 39	$0.19
Commitments Other 40	6,992
Commitments Other 41		2,500
Commitments Other 42		3,000

SUBSEQUENT_EVENTS_Narrative_De

SUBSEQUENT EVENTS (Narrative) (Details)	6 Months Ended
	Feb. 28, 2015	Feb. 28, 2015
	USD ($)	CAD
	M
Subsequent Events 1	590,000	590,000
Subsequent Events 2		0.06
Subsequent Events 3		35,400
Subsequent Events 4	36	36
Subsequent Events 5	0.1
Subsequent Events 6	24	24
Subsequent Events 7	0.15
Subsequent Events 8	24	24
Subsequent Events 9		2,832
Subsequent Events 10	47,200	47,200

Schedule_of_Sharebased_Compens

Schedule of Share-based Compensation, Stock Options, Activity (Details) (USD $)	6 Months Ended
	Feb. 28, 2015
Stock Options And Warrants Schedule Of Share-based Compensation, Stock Options, Activity 1	$3,655,000
Stock Options And Warrants Schedule Of Share-based Compensation, Stock Options, Activity 2	0.33
Stock Options And Warrants Schedule Of Share-based Compensation, Stock Options, Activity 3	-550,000
Stock Options And Warrants Schedule Of Share-based Compensation, Stock Options, Activity 4	0.07
Stock Options And Warrants Schedule Of Share-based Compensation, Stock Options, Activity 5	0.86
Stock Options And Warrants Schedule Of Share-based Compensation, Stock Options, Activity 6	-700,000
Stock Options And Warrants Schedule Of Share-based Compensation, Stock Options, Activity 7	0.1
Stock Options And Warrants Schedule Of Share-based Compensation, Stock Options, Activity 8	2,200,000
Stock Options And Warrants Schedule Of Share-based Compensation, Stock Options, Activity 9	0.1
Stock Options And Warrants Schedule Of Share-based Compensation, Stock Options, Activity 10	$4,605,000
Stock Options And Warrants Schedule Of Share-based Compensation, Stock Options, Activity 11	0.18

Schedule_of_Sharebased_Payment

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details) (USD $)	6 Months Ended
	Feb. 28, 2015
	Y
Stock Options And Warrants Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 1	216.00%
Stock Options And Warrants Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 2	219.00%
Stock Options And Warrants Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 3	204.00%
Stock Options And Warrants Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 4	219.00%
Stock Options And Warrants Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 5	1.63%
Stock Options And Warrants Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 6	1.79%
Stock Options And Warrants Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 7	1.33%
Stock Options And Warrants Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 8	1.79%
Stock Options And Warrants Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 9	5
Stock Options And Warrants Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 10	5
Stock Options And Warrants Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 11	0.00%
Stock Options And Warrants Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 12	0.00%
Stock Options And Warrants Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 13	0.06
Stock Options And Warrants Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 14	$0.07
Stock Options And Warrants Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 15	0.05
Stock Options And Warrants Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 16	$0.69

Disclosure_of_Sharebased_Compe

Disclosure of Share-based Compensation Arrangements by Share-based Payment Award (Details) (USD $)	6 Months Ended	12 Months Ended
	Feb. 28, 2015	Aug. 31, 2014
	Y	Y
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 1	$0.10
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 2	100,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 3	4.72
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 4	0.1
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 5	100,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 6	0.1
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 7	0.1
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 8	2,100,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 9	4.68
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 10	0.1
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 11	2,100,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 12	0.1
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 13	0.5
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 14	50,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 15	4.1
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 16	0.5
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 17	50,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 18	0.5
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 19	0.7
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 20	500,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 21	4.07
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 22	0.7
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 23	250,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 24	0.7
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 25	0.35
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 26	50,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 27	3.93
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 28	0.35
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 29	25,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 30	0.35
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 31	0.16
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 32	250,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 33	3.87
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 34	0.16
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 35	250,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 36	0.16
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 37	0.06
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 38	550,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 39	3.68
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 40	0.06
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 41	550,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 42	0.06
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 43	0.15
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 44	555,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 45	0.96
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 46	0.15
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 47	555,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 48	0.15
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 49	0.15
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 50	150,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 51	1.02
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 52	0.15
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 53	150,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 54	0.15
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 55	0.15
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 56	150,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 57	2.05
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 58	0.15
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 59	150,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 60	0.15
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 61	0.2
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 62	100,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 63	0.69
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 64	0.2
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 65	100,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 66	0.2
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 67	0.25
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 68	50,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 69	1.25
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 70	0.25
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 71	50,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 72	0.25
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 73	4,605,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 74	3.66
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 75	0.18
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 76	4,605,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 77	0.18
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 1		0.5
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 2		50,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 3		4.6
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 4		0.5
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 5		50,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 6		4.6
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 7		0.5
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 8		0.72
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 9		100,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 10		4.59
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 11		0.72
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 12		100,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 13		4.59
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 14		0.72
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 15		0.86
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 16		200,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 17		4.58
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 18		0.86
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 19		200,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 20		4.58
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 21		0.86
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 22		0.7
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 23		500,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 24		4.57
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 25		0.7
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 26		250,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 27		4.57
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 28		0.7
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 29		0.68
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 30		200,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 31		4.53
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 32		0.68
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 33		100,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 34		4.53
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 35		0.68
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 36		0.35
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 37		50,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 38		4.43
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 39		0.35
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 40		50,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 41		4.43
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 42		0.35
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 43		0.16
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 44		250,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 45		4.37
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 46		0.16
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 47		250,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 48		4.37
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 49		0.16
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 50		0.075
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 51		50,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 52		4.34
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 53		0.075
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 54		50,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 55		4.34
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 56		0.075
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 57		0.06
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 58		550,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 59		4.18
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 60		0.06
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 61		550,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 62		4.18
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 63		0.06
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 64		0.1
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 65		300,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 66		0.14
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 67		0.1
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 68		300,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 69		0.14
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 70		0.1
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 71		0.1
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 72		400,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 73		0.33
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 74		0.1
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 75		400,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 76		0.33
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 77		0.1
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 78		0.15
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 79		555,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 80		1.45
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 81		0.15
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 82		555,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 83		1.45
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 84		0.15
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 85		0.15
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 86		150,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 87		1.52
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 88		0.15
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 89		150,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 90		1.52
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 91		0.15
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 92		0.15
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 93		150,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 94		2.55
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 95		0.15
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 96		150,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 97		2.55
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 98		0.15
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 99		0.2
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 100		100,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 101		1.19
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 102		0.2
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 103		100,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 104		1.19
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 105		0.2
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 106		0.25
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 107		50,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 108		1.75
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 109		0.25
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 110		50,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 111		1.75
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 112		0.25
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 113		3,655,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 114		2.85
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 115		0.3
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 116		$3,305,000
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 117		2.67
Stock Options And Warrants Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 118		0.25

Schedule_of_Stockholders_Equit

Schedule of Stockholders' Equity Note, Warrants or Rights, Activity (Details) (USD $)	6 Months Ended
	Feb. 28, 2015
Stock Options And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 1	$13,606,245
Stock Options And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 2	0.14
Stock Options And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 3	1,787,640
Stock Options And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 4	0.1
Stock Options And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 5	$15,393,885
Stock Options And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 6	0.14

Schedule_of_Share_Based_Paymen

Schedule of Share Based Payment Award Equity Note Warrants or Rights Valuation Assumptions (Details) (USD $)	6 Months Ended
	Feb. 28, 2015
	M
Stock Options And Warrants Schedule Of Share Based Payment Award Equity Note Warrants Or Rights Valuation Assumptions 1	$460,000
Stock Options And Warrants Schedule Of Share Based Payment Award Equity Note Warrants Or Rights Valuation Assumptions 2	0.2
Stock Options And Warrants Schedule Of Share Based Payment Award Equity Note Warrants Or Rights Valuation Assumptions 3	136,000
Stock Options And Warrants Schedule Of Share Based Payment Award Equity Note Warrants Or Rights Valuation Assumptions 4	0.2
Stock Options And Warrants Schedule Of Share Based Payment Award Equity Note Warrants Or Rights Valuation Assumptions 5	278,275
Stock Options And Warrants Schedule Of Share Based Payment Award Equity Note Warrants Or Rights Valuation Assumptions 6	0.2
Stock Options And Warrants Schedule Of Share Based Payment Award Equity Note Warrants Or Rights Valuation Assumptions 7	430,670
Stock Options And Warrants Schedule Of Share Based Payment Award Equity Note Warrants Or Rights Valuation Assumptions 8	0.2
Stock Options And Warrants Schedule Of Share Based Payment Award Equity Note Warrants Or Rights Valuation Assumptions 9	1,468,000
Stock Options And Warrants Schedule Of Share Based Payment Award Equity Note Warrants Or Rights Valuation Assumptions 10	0.1
Stock Options And Warrants Schedule Of Share Based Payment Award Equity Note Warrants Or Rights Valuation Assumptions 11	1,438,800
Stock Options And Warrants Schedule Of Share Based Payment Award Equity Note Warrants Or Rights Valuation Assumptions 12	0.1
Stock Options And Warrants Schedule Of Share Based Payment Award Equity Note Warrants Or Rights Valuation Assumptions 13	2,167,160
Stock Options And Warrants Schedule Of Share Based Payment Award Equity Note Warrants Or Rights Valuation Assumptions 14	0.15
Stock Options And Warrants Schedule Of Share Based Payment Award Equity Note Warrants Or Rights Valuation Assumptions 15	7,227,340
Stock Options And Warrants Schedule Of Share Based Payment Award Equity Note Warrants Or Rights Valuation Assumptions 16	0.15
Stock Options And Warrants Schedule Of Share Based Payment Award Equity Note Warrants Or Rights Valuation Assumptions 17	1,787,640
Stock Options And Warrants Schedule Of Share Based Payment Award Equity Note Warrants Or Rights Valuation Assumptions 18	0.1
Stock Options And Warrants Schedule Of Share Based Payment Award Equity Note Warrants Or Rights Valuation Assumptions 19	0.15
Stock Options And Warrants Schedule Of Share Based Payment Award Equity Note Warrants Or Rights Valuation Assumptions 20	24
Stock Options And Warrants Schedule Of Share Based Payment Award Equity Note Warrants Or Rights Valuation Assumptions 21	$15,393,885

Schedule_of_Segment_Reporting_

Schedule of Segment Reporting Information, by Segment (Details) (USD $)	6 Months Ended
	Feb. 28, 2015
Segmented Information Schedule Of Segment Reporting Information, By Segment 1	$0
Segmented Information Schedule Of Segment Reporting Information, By Segment 2	0
Segmented Information Schedule Of Segment Reporting Information, By Segment 3	0
Segmented Information Schedule Of Segment Reporting Information, By Segment 4	0
Segmented Information Schedule Of Segment Reporting Information, By Segment 5	0
Segmented Information Schedule Of Segment Reporting Information, By Segment 6	-394,001
Segmented Information Schedule Of Segment Reporting Information, By Segment 7	-907,653
Segmented Information Schedule Of Segment Reporting Information, By Segment 8	-1,301,654
Segmented Information Schedule Of Segment Reporting Information, By Segment 9	1
Segmented Information Schedule Of Segment Reporting Information, By Segment 10	390,272
Segmented Information Schedule Of Segment Reporting Information, By Segment 11	807,333
Segmented Information Schedule Of Segment Reporting Information, By Segment 12	$1,197,606